Perform Another (Advanced) Search

1.  CenterWatch: New Medical Therapies in Disease Category (11), Alzheimer's Disease
...the results of an open-label extension of a phase II study of PBT-1 (clioquinol) , a copper-zinc attenuator/amyloid-beta aggregation inhibitor for the treatment of Alzheimer’s ...
...2004 Prana Biotechnology reported positive results from an extended phase II trial investigating PBT-1 (clioquinol) , a metal protein attenuating compound for the treatment of Alzheimer’s disease. Results showed that ...
View Page

2.  CenterWatch: New Medical Therapies in Disease Category (336), Chronic Fatigue Syndrome
...the results of an open-label extension of a phase II study of PBT-1 (clioquinol) , a copper-zinc attenuator/amyloid-beta aggregation inhibitor for the treatment of Alzheimer’s ...
View Page

3.  CenterWatch: New Medical Therapies in Disease Category (100), Migraine and Cluster Headaches
...the results of an open-label extension of a phase II study of PBT-1 (clioquinol) , a copper-zinc attenuator/amyloid-beta aggregation inhibitor for the treatment of Alzheimer’s ...
View Page